Cannabinoid scope
Revised wording focuses on THCs and semi-synthetic or synthetic cannabinoids with Δ9-THC-like effects. Do not carry the broader 2026 wording into 2027 automatically.
EDITION WATCH / SOURCE CHECK 08 NOV 2026
2026 → 2027
Published is not yet in force. Effective dates matter.
IN FORCE ON 8 NOVEMBER 2026
2026
Effective 1 January 2026
PUBLISHED / FORTHCOMING
2027
Effective 1 January 2027
Selected highlights, not a complete redline. The current 2027 clean PDF is dated 4 November 2026. Full automated comparison and clause-level review are not implemented.
An explicit route clarification
Vaginal administration joins the listed routes subject to licensed-dose and therapeutic-indication conditions.
More named examples
Additional examples do not necessarily create new prohibitions; some already fall within existing classes.
Monitoring changes ≠ delisting
Out-of-competition monitoring of tramadol and fentanyl ends. Their in-competition prohibition continues.